Announcements Trials
Browse Landscape

Phase

Phase 4 6Phase 2 3Phase 3 2Phase NA 1

Status

Unknown 3Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Lymphoid 1

Conditions

Stomach Neoplasms 1Lymphoma, Non-Hodgkin 1Colorectal Neoplasms 1

Interventions

Cisplatin 267Oxaliplatin 194Carboplatin 189Capecitabine 183Docetaxel 176apatinib 164Paclitaxel 158Bevacizumab 155Gemcitabine 154Radiotherapy 146camrelizumab 145Fluorouracil 144Cyclophosphamide 123Irinotecan 119Drug Therapy 118sintilimab 107Etoposide 99anlotinib 90S 1 (combination) 88Leucovorin 85pembrolizumab 82Pemetrexed 78Doxorubicin 77toripalimab 76tislelizumab 75Dexamethasone 70Trastuzumab 65Neoadjuvant Therapy 64Rituximab 62Cetuximab 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Unknown × entecavir × Clear all
NCT02777814 2019-01-22

Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers

Sun Yat-sen University

Phase 2 Unknown
50 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02777801 2017-10-13

Prophylactic or Preemptive Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B Carriers

Sun Yat-sen University

Phase 2 Unknown
50 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01914744 2013-08-02

Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL

Fudan University

Phase 2 Unknown
82 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡